Molecular MR Imaging of Prostate Cancer

Avan Kader; Julia Brangsch; Jan O Kaufmann; Jing Zhao; Dilyana B Mangarova; Jana Moeckel; Lisa C Adams; Ingolf Sack; Matthias Taupitz; Bernd Hamm; Marcus R Makowski

doi:10.3390/biomedicines9010001

Molecular MR Imaging of Prostate Cancer

Biomedicines. 2020 Dec 22;9(1):1. doi: 10.3390/biomedicines9010001.

Authors

Avan Kader^{1

2}, Julia Brangsch^{1

3}, Jan O Kaufmann^{1

4

5}, Jing Zhao¹, Dilyana B Mangarova^{1

6}, Jana Moeckel¹, Lisa C Adams¹, Ingolf Sack¹, Matthias Taupitz¹, Bernd Hamm¹, Marcus R Makowski^{1

7

8}

Affiliations

¹ Department of Radiology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Charitéplatz 1, 10117 Berlin, Germany.
² Department of Biology, Chemistry and Pharmacy, Institute of Biology, Freie Universität Berlin, Königin-Luise-Str. 1-3, 14195 Berlin, Germany.
³ Department of Veterinary Medicine, Institute of Animal Welfare, Animal Behavior and Laboratory Animal Science, Freie Universität Berlin, Königsweg 67, Building 21, 14163 Berlin, Germany.
⁴ Division 1.5 Protein Analysis, Federal Institute for Materials Research and Testing (BAM), Richard-Willstätter-Str. 11, 12489 Berlin, Germany.
⁵ Department of Chemistry, Humboldt-Universität zu Berlin, Brook-Taylor-Str. 2, 12489 Berlin, Germany.
⁶ Department of Veterinary Medicine, Institute of Veterinary Pathology, Freie Universität Berlin, Robert-von-Ostertag-Str. 15, Building 12, 14163 Berlin, Germany.
⁷ School of Biomedical Engineering and Imaging Sciences, King's College London, St Thomas' Hospital Westminster Bridge Road, London SE1 7EH, UK.
⁸ Department of Diagnostic and Interventional Radiology, School of Medicine & Klinikum Rechts der Isar, Technical University of Munich, Munich (TUM), Ismaninger Str. 22, 81675 München, Germany.

Abstract

This review summarizes recent developments regarding molecular imaging markers for magnetic resonance imaging (MRI) of prostate cancer (PCa). Currently, the clinical standard includes MR imaging using unspecific gadolinium-based contrast agents. Specific molecular probes for the diagnosis of PCa could improve the molecular characterization of the tumor in a non-invasive examination. Furthermore, molecular probes could enable targeted therapies to suppress tumor growth or reduce the tumor size.

Keywords: magnetic resonance imaging; molecular imaging; molecular marker; prostate cancer.

Publication types

Review

Grants and funding

SFB 1340/1 2018/Deutsche Forschungsgemeinschaft